IL1B and lung cancer: Two recent studies reported that canakinumab targeting the interleukin-1β (IL-1β) immunity pathway was regarded as new anti-inflammatory strategies to reduce atherosclerotic disease (Ridker et al., 2017a) and incident lung cancer with atherosclerosis in patient (Ridker et al., 2017b), proving that anti-inflammatory therapy is a valid curative method to lower cardiovascular events.